文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

脂蛋白(a)与高血压。

Lipoprotein (a) and Hypertension.

机构信息

Dobney Hypertension Centre, Medical School, University of Western Australia, Perth, Australia.

Medical School, University of Western Australia, Perth, Australia.

出版信息

Curr Hypertens Rep. 2021 Dec 9;23(12):44. doi: 10.1007/s11906-021-01161-6.


DOI:10.1007/s11906-021-01161-6
PMID:34888749
Abstract

PURPOSE OF REVIEW: To provide an overview of the associations between elevated blood pressure and lipoprotein (a) and possible causal links, as well as data on the prevalence of elevated lipoprotein (a) in a cohort of hypertensive patients. RECENT FINDINGS: Elevated lipoprotein (a) is now considered to be an independent and causal risk factor for atherosclerotic cardiovascular disease and calcific aortic valve disease. Despite this, there are limited data demonstrating an association between elevated lipoprotein (a) and hypertension. Further, there is limited mechanistic data linking lipoprotein (a) and hypertension through either renal impairment or direct effects on the vasculature. Despite the links between lipoprotein (a) and atherosclerosis, there are limited data demonstrating an association with hypertension. Evidence from our clinic suggests that ~ 30% of the patients in this at-risk, hypertensive cohort had elevated lipoprotein (a) levels and that measurement of lipoprotein (a) maybe useful in risk stratification.

摘要

目的综述: 脂蛋白(a)与高血压之间的关联及可能的因果关系,并提供高血压患者队列中脂蛋白(a)升高的患病率数据。

最新发现: 脂蛋白(a)现在被认为是动脉粥样硬化性心血管疾病和钙化主动脉瓣疾病的独立和因果危险因素。尽管如此,目前仅有有限的数据表明脂蛋白(a)升高与高血压之间存在关联。此外,通过肾脏损害或对血管的直接作用将脂蛋白(a)与高血压联系起来的机制数据也很有限。尽管脂蛋白(a)与动脉粥样硬化之间存在关联,但目前仅有有限的数据表明其与高血压有关。我们临床的证据表明,在这个高危、高血压的患者队列中,约有 30%的患者脂蛋白(a)水平升高,脂蛋白(a)的测量可能有助于风险分层。

相似文献

[1]
Lipoprotein (a) and Hypertension.

Curr Hypertens Rep. 2021-12-9

[2]
Lipoprotein(a) and calcific aortic valve stenosis: A systematic review.

Prog Cardiovasc Dis. 2020-6-8

[3]
Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis.

Curr Opin Cardiol. 2016-7

[4]
What is the ultimate test that lowering lipoprotein(a) is beneficial for cardiovascular disease and aortic stenosis?

Curr Opin Lipidol. 2014-12

[5]
The Riskier Lipid: What Is on the HORIZON for Lipoprotein (a) and Should There Be Lp(a) Screening for All?

Curr Cardiol Rep. 2021-7-1

[6]
New Frontiers in Lp(a)-Targeted Therapies.

Trends Pharmacol Sci. 2019-2-4

[7]
Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia.

Atherosclerosis. 2018-12-7

[8]
The journey towards understanding lipoprotein(a) and cardiovascular disease risk: are we there yet?

Curr Opin Lipidol. 2018-6

[9]
Potential Causality and Emerging Medical Therapies for Lipoprotein(a) and Its Associated Oxidized Phospholipids in Calcific Aortic Valve Stenosis.

Circ Res. 2019-2

[10]
Measuring lipoprotein(a) for cardiovascular disease prevention - in whom and when?

Curr Opin Cardiol. 2024-1-1

引用本文的文献

[1]
Lipoprotein(a) and panvascular disease.

Lipids Health Dis. 2025-5-24

[2]
Development of a fully automated latex-enhanced immunoturbidimetric method for quantitative serum Lp(a) measurement.

Biotechnol Lett. 2025-3-6

[3]
Association between lipoprotein(a) and cardiovascular disease in patients undergoing coronary angiography.

Herz. 2024-10

[4]
Association of lipoprotein(a) with left ventricular hypertrophy assessed by electrocardiogram in adults: a large cross-sectional study.

Front Endocrinol (Lausanne). 2023

[5]
Intracranial Aneurysms and Lipid Metabolism Disorders: From Molecular Mechanisms to Clinical Implications.

Biomolecules. 2023-11-14

[6]
Lipoprotein(a): Just an Innocent Bystander in Arterial Hypertension?

Int J Mol Sci. 2023-8-29

[7]
Current Data and New Insights into the Genetic Factors of Atherogenic Dyslipidemia Associated with Metabolic Syndrome.

Diagnostics (Basel). 2023-7-12

[8]
Lipoprotein(a) and heart failure: a systematic review.

Heart Fail Rev. 2023-11

[9]
Association of Lp(a) (Lipoprotein[a]) and Hypertension in Primary Prevention of Cardiovascular Disease: The MESA.

Hypertension. 2023-2

[10]
The relationship between lipoprotein(a) and risk of cardiovascular disease: a Mendelian randomization analysis.

Eur J Med Res. 2022-10-27

本文引用的文献

[1]
Development of an LC-MS/MS Proposed Candidate Reference Method for the Standardization of Analytical Methods to Measure Lipoprotein(a).

Clin Chem. 2021-3-1

[2]
Lipoprotein (a) and diabetes mellitus: causes and consequences.

Curr Opin Endocrinol Diabetes Obes. 2021-4-1

[3]
Serum lipoprotein (a) associates with a higher risk of reduced renal function: a prospective investigation.

J Lipid Res. 2020-10

[4]
Lipid management in people with peripheral artery disease.

Curr Opin Lipidol. 2019-12

[5]
Response to 'Lipoprotein(a): it is not the cholesterol content: it is the apolipoprotein(a)!'.

Eur Heart J. 2019-11-14

[6]
Elevated Lipoprotein(a) and Risk of Ischemic Stroke.

J Am Coll Cardiol. 2019-7-9

[7]
Statin therapy increases lipoprotein(a) levels.

Eur Heart J. 2020-6-21

[8]
Prediction of cardiovascular risk by Lp(a) concentrations or genetic variants within the LPA gene region.

Clin Res Cardiol Suppl. 2019-4

[9]
Potential Causality and Emerging Medical Therapies for Lipoprotein(a) and Its Associated Oxidized Phospholipids in Calcific Aortic Valve Stenosis.

Circ Res. 2019-2

[10]
Lipoprotein(a) in clinical practice: New perspectives from basic and translational science.

Crit Rev Clin Lab Sci. 2017-12-20

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索